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The duration and level of virus excretion in blood
and faecesof patientswithhepatitisAvirus (HAV)
infection were studied in relation to levels of
alanine aminotransferase (ALT), disease severity
and HAV genotype. Clinical data, blood and
faeces were collected from 27 patients with acute
hepatitis A (median age: 33 years) for amaximum
of26weeks.Singleblooddonations from55other
patients with acute HAV (median age: 32 years)
were also used. Virus loads were quantified by
competitive nested RT-PCR. HAVwas excreted in
faeces for a median period of 81 days after
disease onset, with 50% of patients still excreting
high levels at Day 36 (2 106–2108 copies/ml
faeces suspension). Viraemia was detected, but
not quantifiable, for a median period of 42 days.
In the first 10 days of illness, higher ALT levels
were correlated with higher viraemia levels.
Comparison of patients infected with genotype
1a with those infected with type 1b did not differ
significantly in terms of the duration of HAV
excretion or jaundice. In conclusion, faecal
excretion of HAV is at a high titre in the first
month, perhaps making patients infectious for a
longer period than assumed currently. Blood
banks should be aware that viraemia may be
present for more than 1 month, and genotype
did not affect the duration of virus excretion
or jaundice. J. Med. Virol. 78:1398–1405,
2006.  2006 Wiley-Liss, Inc.
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HAV levels
INTRODUCTION
Hepatitis A virus (HAV) belongs to thePicornaviridae
family and is classified in its own genus, Hepatovirus.
Infection takes place mainly via the faecal-oral route
throughperson-to-person contact. In the late incubation
period and at onset of illness very large numbers of HAV
particles are excreted in faeces until alanine amino-
transferase (ALT) reaches peakelevation [Ciocca, 2000].
Therefore, patientswithHAVare considered contagious
from 1–2 weeks before onset of symptoms until 1–
2 weeks afterward [Koff, 1998; Center for Disease
Control and Prevention, 2004]. However, faecal excre-
tion can last up to 3 months and longer [Yotsuyanagi,
1996; Costa-Mattioli et al., 2002a], indicating that
patients may be contagious for a longer period than
assumed previously.
In addition to faecal excretion, the virus is also
present in blood [Center for Disease Control and
Prevention, 2004]. HAV viraemia can exceed 3 months
in immunocompetent patients [Bower et al., 2000;
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Costa-Mattioli et al., 2002b; Sagnelli et al., 2003;
Normann et al., 2004] and in one HIV-infected patient,
it was detected for 256 days [Costa-Mattioli et al.,
2002a]. Parenteral transmission has been reported by
blood transfusion and blood products [Mannucci et al.,
1994; Soucie et al., 1998] underlining the importance
of detection of HAV viraemia. However, data on the
duration of HAV excretion remain limited.
Because acute HAV infection is self-limiting, long-
itudinal studies inwhich clinical dataare collectedalong
with samples are uncommon. For a follow-up study,
blood and faecal sampleswere collected from27 patients
with acute hepatitis A infection for amaximumperiod of
26 weeks. Our aim was to determine the median
duration of HAV excretion in faeces and blood and thus
the period of possible infectiousness. Additionally, in
55 other patients whose HAV had been typed [van
Steenbergen et al., 2004], it was investigated whether
the degree of liver damage affected duration and level of
HAV excretion in faeces and viraemia level, and
whether HAV genotype affected the duration of HAV
excretion and jaundice.
MATERIALS AND METHODS
Participants
For the follow-up study, all patientswhowere positive
for anti-HAV immunoglobulin M (anti-HAV IgM(þ))
and reported between August 2003 and August 2004 to
the Public Health Services in Amsterdam, Brabant,
South Limburg, Groningen, South-Holland South and
South-Holland North were approached.
Participants were asked to sign an informed consent
form and to donate a maximum of nine faecal samples
and three blood samples over 26 weeks. To prevent
distress in children younger than 12 years, they were
not required to donate multiple blood samples, but only
the one sample used for detecting anti-HAV IgM. The
participantsweredividedat random into groupsAandB
to donate on different schedules (Table I) to obtain a
maximum number of time points after infection. In
weeks1–4after start of symptoms, participantsdonated
three faecal samples; in weeks 5–26 they donated one
faecal sample every 4 weeks. If three consecutive faecal
sampleswere negative in theHAVPCRbefore the end of
the 26-week period, follow-up for that patient was
stopped. Adults were asked to donate three blood
samples in the first 4 weeks of illness, but a few samples
were received after more than 4 weeks. Participants
were asked to complete a structured questionnaire each
time they sent in a faecal sample. It asked about the
presence and duration of symptoms such as jaundice,
vomiting, nausea, fatigue, medications and co-infec-
tions. The blood samples were used to determine levels
of ALT to quantify liver damage. Patients with ALT
levels above normal, that is,>45 IU/L blood (378C),were
considered to have abnormal liver function.
Additionally, blood samples were used representing
55 sporadic HAV cases who participated previously in
an HAV typing study [Bruisten et al., 2001; van
J. Med. Virol. DOI 10.1002/jmv
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Steenbergen et al., 2004], to study the relation between
the degree of liver damage and the virus load. Patients
were reported from December 2000 to February 2004 to
the Amsterdam health service (HS).
Time Definition
Because the production date of the faecal sampleswas
often unknown, the date on which it was received was
used. The sampling time was calculated as the days
between the first day of symptoms (jaundice) and
the date the sample was received. Sampling time in
blood was the number of days between the first day of
symptoms and the donation date.
Blood and faecal samples from individual follow-up
participantswere considered tobemeasured in the same
period (i.e. one measurement), if faeces were provided
within 5 days after giving a blood sample.
RNA Isolation, Detection, Sequencing and
Phylogenetic Analysis
RNA extraction, nested RT-PCR, sequencing and
phylogenetic analysis were carried out as described
previously [Bruisten et al., 2001; van Steenbergen et al.,
2004; Tjon et al., 2005]. The detection RT-PCR was
carried out in an end volume of 25 ml with an input of 5 ml
RNA from patient material.
Random hexamer primers were used for reverse
transcription. PCR primers for nested amplification of
the VP3-VP1 region and the VP1-P2a region of the HAV
genome were used as described previously [Bruisten
et al., 2001; van Steenbergen et al., 2004; Tjon et al.,
2005]. All primers were synthesised by Isogen Life
Science (Maarssen, The Netherlands).
Construction of Competitor RNA
The competitor was created from RNA isolated from
virus culture HAVcyt/HB1.1 [Brack et al., 1998] with
Tripure isolation reagent (Roche, Almere, The Nether-
lands). Full-length HAV RNA was resuspended in 50 ml
Tris-HCl (10mM, pH 8.0) and stored at808Cuntil use.
The method was adapted from Diviacco et al. [1992].
Two RT-PCRs were performed with the Access RT-PCR
kit (Promega, Leiden, The Netherlands). The sequences
of the primers used in the RT-PCR reactions are shown
in Table II. The 25 ml RT-PCRmixtures contained 0.5 ml
HAVcyt/HB1.1 RNA, 1 AMV/Tfl reaction buffer, 200 mM
dNTP, 1.5 mM MgSO4, 10 ng of the sense and the
anti-sense primer, 0.1UAMVreverse transcriptase and
0.1 U Tfl DNA polymerase. The RT step was carried
out at 488C for 45min and 948C for 2min. Subsequently,
35 amplification cycles were carried out at 948C for
30 sec, 558C for 30 sec, 688C for 90 sec, and terminated
with 688C for 7 min. The amplification products of
RT-PCR1 (175 bp) and RT-PCR2 (222 bp) contain an
overlapping region of 20 bp with restriction sites EcoRI
and HindIII (Table II). This region was used for 1:1
hybridisation of PCR1 and PCR2 amplimers. Subse-
quently, 0.2 ml of the mixture and primers VP1-4-sense-
NcoI andVP1-6-SalI (Table II)wereadded ina25ml PCR
mix and amplification was carried out [Bruisten et al.,
2001]. The resulting 397 bp amplimer was verified on a
1% agarose gel, isolated with the Qiagen gel extraction
kit (Qiagen Benelux B.V., Venlo, The Netherlands) and
dissolved in 50 ml Tris-HCl (10 mM, pH 8.0). The
fragment was cloned into a pGEM5Zf(þ) vector and
grown in JM109 bacteria (Promega Benelux B.V.,
Leiden, The Netherlands). Plasmid DNA was isolated
from a recombinant clone and linearised by incubation
at 958C for 2 min and placement on ice for 5 min.
Competitor RNA was made using T7 polymerase
(Promega Benelux B.V.) and contaminating DNA was
removed with RQ1 Dnase (Promega Benelux B.V.)
according to the manufacturers’ protocols.
Quantitative RT-PCR
Serial dilutions of competitor RNA were amplified by
nested PCR with and without an RT step according to
Bruisten et al. [2001] to determine the presence of
contaminating DNA. Dilution samples that were nega-
tive in the PCR reactions without the RT step were used
for quantitative RT-PCR with patient material. Two
methods were used for calculating the concentration of
the competitor RNA. The first method was based on the
OD260 value measured by spectrophotometer of the
competitor RNA, which was 0.024, and the Avogadro
formula. The total length of the competitor RNA is 443
nucleotides, resulting in a concentration of the compe-
titor RNA starting solution of 41011 copies/ml. The
secondmethodwas based on the fact thatRNAdetection
by RT-PCR is possible from 10 to 20 copies per reaction,
assuming a 10% efficiency of the cDNA step and the
potency to detect 1–2 copies of target cDNA. Using this
method we calculated that the concentration of the
competitor RNA starting solution was about 41012
copies/ml. The average of these numbers was calculated
J. Med. Virol. DOI 10.1002/jmv
TABLE II. Primer Sequences Used in the Two RT-PCRs to Construct the Competitor
Primer Sequence 50-30 Nucl nra
RT-PCR1 VP1-4s NcoI TAC/CATGGcgttgcttcccatgtcaga 2131–2149
VP-mut-as EcoRI/HindIII ccGAATT/CcgcgAAGC/Ttgcaacattctgttctgtagaaa 2259–2278
RT-PCR2 VP1-6 SalI GCG/TCGACcatatgatctgatgtatgt 2455–2473
VP-s-mut EcoRI/HindIII gcA/AGCTTcgcgG/AATTCggccagatccccaagttgtat 2279–2298
aNucleotide numbering is according to strain HAVcyt HB1.1 [Brack et al., 1998]. The underlined part of the primer sequences written in capital
letters indicates restriction sites. The EcoRI/HindIII sites are in a 20 bp region, which is present in the competitor sequence but not in wild-type
HAV.
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and the competitor concentration was set at 21012
copies/ml.
Serial tenfold dilutions of the competitor RNA were
divided into aliquots with Tris-HCl (10 mM, pH 8.0)
containing 0.5 U/ml Rnasin. The quantitative RT-PCR
was performed according to the HAV RT-PCR protocols
described previously [van Steenbergen et al., 2004; Tjon
et al., 2005] in an endvolumeof 25 mlwith an input of 2ml
competitor RNA and 2 ml RNA from patient material.
Amplification of the competitor resulted in an amplicon
of 267 bp, while the amplicon size of patient-derived
HAV cDNA was 247 bp. The qualitative RT-PCR had a
higher sensitivity than the quantitative RT-PCR con-
cerning detection of patient-derived HAV RNA because
no competitor RNA was added. Hence, HAV RNA
detected with the qualitative RT-PCR was not
always quantifiable. The number of HAV copies in a
stool samplewere calculated permillilitre of a 10%–20%
suspension of fresh stool in phosphate buffered saline;
hereafter referred to as ‘‘faeces suspension’’. Quantita-
tion was possible from virus load levels of 2 103 copies/
ml faecal suspension and from 1 103 copies/ml blood.
Statistical Analysis
Statistical analyses were performed with SAS [SAS
statistical package, 2005b], R [R statistical package,
2005a] and SPSS 12.0 [SPSS 12.0, 2005c] software for
Windows. The distribution of the time until virus loads
in faeces and blood were below a certain level was
estimated, for example undetectable by RT-PCR, using
the nonparametric maximum likelihood estimator for
interval censored data [Groeneboom, 1996].
Relations between the three markers (ALT and virus
levels in blood and in faeces) were analysed in a linear
regression model after transformation to the log-scale.
For each marker combination, two models were fitted;
each marker was used as dependent variable to predict
the other.
The Mann–Whitney test was used to determine if
HAV genotype influenced duration of HAV excretion in
faeces and/or jaundice. The test was also used to
determine if liver damage influenced the duration of
HAV excretion, comparing patients with ALT levels
above and below the median of 1,000 IU/ml blood.
RESULTS
General Characteristics of Participants
Follow-up study. Of the anti-HAV IgM positive
cases reported from August 2003 to 2004 at the
participating health services, 27 people participated in
the follow-up study. As shown in Table III, these
included 18 men and 9 women (median age 33 years;
interquartile range (IQR) 23–42 years), of whom 17
persons were infected with subtype 1a strains (63%), 7
with subtype 1b strains (26%) and 3 with subtype 3a
strains (11%).
All but two participants reported jaundice. Of these,
84% (21/25) also reported the duration of jaundice,
which lasted for a median period of 17 days (IQR: 5–
74 days). Comparing patients infected with genotype 1a
versus genotype 1b,we foundno significant difference in
duration of jaundice (Mann–Whitney test: P¼ 0.89) or
duration of HAV excretion in faeces (P¼0.13).
HAV-Typing Study Participants
These 55 patients consisted of 43 men and 12 women
(median age: 32 years; IQR 12–38 years) (Table III).
There were 39 persons infected with subtype 1a strains
(71%), 14with subtype 1b (25.5%) and 2with subtype 3a
(3.6%). Of the total, 49 persons (89%) reported jaundice.
Time Course of Virus Load Levels
and ALT Among Patients
In concordance with the comparisons mentioned
above, there were no observable differences per geno-
type concerning the course of HAV excretion. In The
Netherlands, there are two main risk groups among
whom different HAV genotypes circulate: homosexual
men are infected with genotype 1a strains, while
travelers to HAV endemic countries are infected mainly
with either genotype 1b strains (Morocco, Turkey, etc.)
or genotype 3a strains (Pakistan, India) [van Steenber-
gen et al., 2004]. The patterns of patients infected with
genotype 1a, 1b or 3a are shown in Figure 1a–c.
Figure 1a represents a 26-year-old homosexual man
infected with a genotype 1a strain. He reported
anonymous sex in saunas as a risk factor. He was
jaundiced for 16 days and a HAV faecal excretion was
detected up to 98 days after disease onset.
Figure 1b depicts a 31-year-old patient who was
infected in Morocco with a genotype 1b strain. He was
jaundiced for 21 days, and virus excretion was detected
until 70 days after onset of illness.
Figure 1c represents an 11-year-old patient who
became infected in Pakistan with a genotype 3a strain.
The patient was jaundiced for 18 days and HAV
excretion was detected for 76 days.
J. Med. Virol. DOI 10.1002/jmv
TABLE III. Characteristics of the Participants in the
Follow-Up and the HAV Typing Study
Follow-up study HAV typing study
No. of patients 27 55
Median age (years) 33 (IQR 23-42) 32 (IQR 12-38)
Gender
Male 18 (67%) 43 (78%)
Female 9 (33%) 12 (22%)
Genotype
1a 17 (63%) 39 (71%)
1b 7 (26%) 14 (25.5%)
3a 3 (11%) 2 (3.6%)
Jaundice 25/27 (93%) 49/55 (89%)
Median duration of
jaundice (days)
17 NA
Median duration of
HAV excretion
(days)
81 NA
NA, not applicable.
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HAV Detection and Quantitation in Faeces
Hepatitis A virus (HAV) faecal excretionwas detected
for an estimated median period of 81 days after onset of
symptoms in samples of the 27 follow-up study partici-
pants (Fig. 2). Faecal excretion was never shorter than
57 days, with a maximum of 127 days. Fifty percent of
the participants still excreted at least 2106–2 108
copies/ml faeces suspension at 36 days after onset of
symptoms. After 65 days this had declined to 10% of
patients. The lowest quantifiable level, 2 103 copies/ml
faeces suspension, was detected for a median period of
60 days.
HAV Detection and Quantitation in Blood
In the follow-up study (n¼27), serum samples were
provided from 1 day before onset of illness to 74 days
after the onset of symptoms. The estimated median
period in which HAV was detected in blood was 42 days
after disease onset (Fig. 2). At 60 days after the onset, all
blood samples were estimated to be HAV-negative.
ThePCRresults of the seraprovidedbyparticipants of
both the follow-up and HAV typing study are shown in
Figure 3. In total, 119 samples taken from 82 partici-
pants were tested, since 22 follow-up patients donated
more than one blood sample. Again, we found that the
proportion of PCR-positive sera declined over time. It
J. Med. Virol. DOI 10.1002/jmv
Fig. 2. Curves for virus excretion levels at different time points. The
black curves show the estimated percentage of patients over time that
have a virus load in faeces above a certain limit. The grey curve shows
the last time points at which sera were HAV-positive in the qualitative
RT-PCR. The horizontal line is the median value.
Fig. 1. a–c: Time course of virus load and ALT level in three
patients. The left Y-axis shows the logarithm of virus load in linear
scale per ml faeces suspension or per ml blood. Logload¼1: detection
limit qualitative RT-PCR. Logload¼ 1.5: detection limit quantitative
RT-PCR. Logload¼2: Quantification limit. The right Y-axis shows the
ALT levels in log scale in IU/ml blood. The X-axis shows the number of
days after onset of symptoms. Duration of jaundice is depicted by the
grey bar on the X-axis. a: Patient 1 is a 26-year-old homosexual man
who got infected with a type 1a virus by anonymous sex in public
venues. He was jaundiced for 16 days. b: Patient 2 is a 31-year-old man
who got infected with a genotype 1b strain in Morocco. He was
jaundiced for 21 days. c: Patient 3 is an 11-year-old boywho got infected
with a genotype 3a strain in Pakistan. He was jaundiced for 18 days.
Fig. 3. Detectability ofHAVviraemia according to days after onset of
illness. The Y-axis shows the percentage of PCR-positive (grey) blood
samples donated by participants of the follow-up and the HAV-typing
study.All 72 sera (100%) donatedwithin thefirst 10 days of illnesswere
PCR-positive, whereas 80% of the sera donatedmore than 40 days after
onset were PCR-negative.
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was100% in theperiodup to 10daysafter onset of illness
and declined to 20% after 40 days (Fig. 3).
Taking into account one serum sample per patient
obtained at different time points after the onset of
disease, it was found that the median virus load levels
varied at different time points. In the first 10 days of
illness, themedian virus load levelwas 1106 copies/ml
blood (95% confidence interval (CI): 5.2 105–1.9106
copies/ml blood; n¼ 69). After 10 days, the median virus
load of the donated sera was below quantitation level
(<103 copies/ml).
Relation Between ALT Levels and Virus
Levels in Blood and in Faeces
ALT levels and virus load in blood. To deter-
mine if thedegree of liver damage influencedvirus levels
in blood in the first 10 days of illness and vice versa, data
were analysed from follow-up and HAV typing-study
participants (n¼ 64). Spearman analysis revealed a
significant association between liver damage and the
HAV level in serum (r¼0.354; P¼0.004). This was
corroborated by the results from linear regression
analysis, which showed that if ALT levels decreased
with 1log10 IU/L blood, viraemia levels decreased with
0.81log10 copies/ml blood (P¼0.017), and vice versa, if
viraemia levels decreased with 1log10 copies/ml blood,
ALT levels decreased with 0.11log10 IU/L blood
(P¼0.017). To minimize the confounding effect of time,
these analyses were repeated with data of the first
5 days of illness, which yielded similar results.
ALT levels and virus load in faeces. Nine
participants provided blood and faeces in the same
period (5 days) within the first 10 days of illness. Using
Spearman analysis, a strong positive correlation was
found between the virus level in blood and in faeces
(r¼0.942;P< 0.01).Nosignificant correlationwas found
between ALT levels and virus load in faeces during this
period (r¼ 0.248; P¼0.520).
ALT levels and duration of HAV excretion in
faeces. The possible relation between liver damage
and the duration of HAV excretion in faeces was of
interest. Upon analysis, no difference was found in
duration of HAV excretion between persons with ALT
levels above themedian (1,000 IU/ml blood) versus ALT
levels below the median in the first 10 days of illness
(Mann–Whitney test: P¼0.5; n¼ 16).
DISCUSSION
Due to the acute and self-limiting nature of HAV
infection, sequential collection of samples combined
with clinical data from patients is uncommon. Informa-
tion on the duration and level of HAV excretion in blood
and in faeces is therefore limited despite its importance
for disease control.
To elucidate these matters, clinical data and serial
blood and faeces samples were collected from 27 acute
hepatitis A patients for half a year. The biochemical and
clinical data were combined with quantitative RT-PCR
results to study possible relations between symptomatic
disease and the duration and level of HAV excretion.
In other studies, the real-time PCR method was used
to quantify HAV loads in sera. These real-time PCRs
target the 50 noncoding region and virus loads were
quantified with an external standard [Costa-Mattioli
et al., 2002b;Rezende et al., 2003;Normannet al., 2004].
At the onset of this study, a real-time PCR was
compared with a competitive nested RT-PCR, targeting
the VP3-VP1 region (data not shown). An internal
standard was used for both virus quantitation, and as
an inhibition control for PCR of faeces-derived RNA
samples. Tests using the real-time PCR showed a
significant increase in the fluorescent signal represent-
ing amplification of the internal standard, whereas
almost no increase in fluorescent signal was detected for
amplification of thewild-typeHAVcDNA.Nevertheless,
both the internal standardand thewild-typeHAVcDNA
were amplified during the reaction, since amplicons of
the expected sizes were visible on acryl-amide gels.
Unfortunately, we were not able to solve this problem
and therefore chose to use the competitive nested RT-
PCR that is described in the present study, as this
yielded more reproducible and robust results.
The results show thatHAV is detectable in faeces for a
median period of 81 days after onset of symptoms,with a
maximum of 127 days. Although the literature on this
subject is sparse, studies with fewer patients describe
similar findings of HAV excretion periods in faeces from
52 days post-onset up to 89 days in healthy individuals
[Yotsuyanagi, 1996; Polish et al., 1999; Flehmig et al.,
2000; Chitambar et al., 2001; Costa-Mattioli et al.,
2002a]. HIV-positive persons may excrete the virus for
even longer periods, since one study found that anHIV-1
infected person still excreted 5 106 copies/g faeces 106
days after the onset of illness [Costa-Mattioli et al.,
2002a].
Of ourpatients, 50%were still sheddingHAV in faeces
at 36 days, at the same high levels as at disease onset
(Fig. 2). One study reported successful infection of two
tamarins by inoculation with a suspension of faeces
donated 27 days after the ALT peak of the human
patient [Polish et al., 1999]. The animals seroconverted
and excreted HAV in blood and in faeces after 15 and 21
days, respectively. Thus, patients still excreting high
levels of HAV in faeces after 1 month may still be
infectious.
Sera collected during the present study were HAV
RNA-positive for amedianperiod of 42days after illness.
Other studies report viraemic periods varying from 22
up to 490 days [Bower et al., 2000; Kwon et al., 2000; Ida
et al., 2002; Costa-Mattioli et al., 2002b; Sagnelli et al.,
2003; Normann et al., 2004].
AlthoughHAV transmission by blood products is rare,
there have been several reports on HAV outbreaks due
to contaminated blood products [Mannucci et al., 1994;
Robertson et al., 1998; Soucie et al., 1998; Chudy et al.,
1999; Gowland et al., 2004; Heitmann et al., 2005].
To prevent contamination of blood products in The
Netherlands, HAV patients are excluded from donating
J. Med. Virol. DOI 10.1002/jmv
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blood for 4weeksafter clinical symptomsare resolved, or
6 weeks in the case of contact with a HAV patient. Since
the patients had jaundice for amedian period of 17 days,
and elevated ALT levels for a median period of 16 days,
the present study suggests that most HAV patients are
probably HAV RNA-negative by the end of the 4–
6 weeks of exclusion. However, blood donors without
any HAV symptoms and those with prolonged viraemia
mustalsobe taken intoaccount, especially sincedonated
blood is not tested for the presence of HAV in The
Netherlands. An even greater risk to blood supplies is
present during the period before HAV antibodies,
increased liver enzyme levels and HAV symptoms are
detected [Gowland et al., 2004; Heitmann et al., 2005].
Weimer et al. [2002] reported awindowperiod of 2weeks
in which HAV-infected patients had high HAV levels in
blood with normal ALT levels before onset of illness.
PCR techniques can reduce this window period and
increase the safety of blood products, especially since
HAV is 10,000 times more infectious by the intravenous
route than orally, and contaminated blood products can
increase morbidity and mortality in already ill patients
treated with these products [Purcell et al., 2002].
It was found that in the first 10 days after onset of
illness, ALT levels were correlated positively with
viraemic levels in blood. However, no indications were
found that the degree of liver damage during this period
influenced duration of HAV excretion in faeces. Other
studies have found thatALTandHAV levels in blood are
correlated positively [Fujiwara et al., 1997; Normann
et al., 2004; Sainokami et al., 2005]. The results of the
present study support the findings of Bower et al. [2000]
who detected HAV levels of 104–105 plaque forming
units (pfu)/ml up to 20 days prior to theALTpeak. These
levels declined to 1–10 pfu/ml 30 days after the ALT
peak.
The factors that cause liver damage during HAV
infection are still poorly understood. One hypothesis is
that hepatic disease is caused by the patient’s immune
systemas it attempts to clear the virus [Vallbracht et al.,
1986; Brack et al., 2002; Rezende et al., 2003]. Age and
underlying disease, as well as medication, can influence
disease outcome. Rezende et al. [2003] reported that
patients with HAV-related fulminant hepatitis had low
HAV levels in blood in spite of hepatocyte necrosis. This
finding is in agreementwith Sainokami et al. [2005]who
found that ALT levels and virus load were significantly
correlated in patients with mild HAV-related symp-
toms, but not in thosewith severe symptoms. In contrast
to the position in vivo, wild-type HAV can persistently
infect human cell lines without causing observable
cytopathogenicity [Vallbracht et al., 1984]. Cytotoxic
peripheral blood lymphocytes taken from HAV patients
have been shown to induce cytolysis in HAV-infected
cell cultures, whereas lymphocytes from noninfected
persons did not have this effect [Vallbracht et al., 1986;
Maier et al., 1988]. Accordingly, one would expect
immunocompromised persons to have persistent
HAV infection. Reportedly, immunocompromised HIV-
infected persons are HAV-viraemic for a longer period
than expected [Ida et al., 2002; Costa-Mattioli et al.,
2002a] and one study found that they show less elevated
ALT levels and are longer viraemic than HIV-negative
patients [Ida et al., 2002]. Another study found that
neonates still excreted HAV 4–5 months after infection
[Rosenblum et al., 1991]. Hence, our finding that the
virus load in blood is associated positively with liver
damage supports the notion that HAV clearance in
hepatocytes is immunomodulated.
On the other hand, increased disease severity may
be associated with viral factors, such as genotype
and nucleotide changes in, for example the 50-non-
translated-region of the virus [Fujiwara et al., 2002]. No
indication was found in this study that genotype
influenced duration of jaundice or HAV excretion, nor
did other studies looking for an association between
HAV genotype and disease severity [Fujiwara et al.,
2003; Rezende et al., 2003; Normann et al., 2004]. The
findings show that HAV faecal excretion is high in
the first month of illness, suggesting that patients may
be infectious for a longer period than currently assumed.
Furthermore, HAV patients can be viraemic for up to
2 months, which has to be taken into account by blood
banks. Finally, a positive associationwas foundbetween
ALT and viraemia levels during the first 10 days of
illness.
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